"This rapidly expanding portfolio from DiscoverX for the immuno-oncology market will enable researchers to take advantage of our extensive experience in screening and profiling large numbers of molecules, enabling the rapid prioritization of drug candidates," said Todd R. Nelson, Ph.D., CEO of DiscoverX. "With cell-based assays available for both stimulatory and inhibitory targets such as PD-1, CTLA4, CD137, and OX40, this service provides researchers an innovative option to test novel molecules with agility and specificity in their quest to find the next powerful immunotherapy treatment."
For more information on the PathHunter iONCscan services, visit discoverx.com.
DiscoverX Corporation, headquartered in Fremont, CA, USA, is a leader in the design, manufacture and sale of biochemical and cell-based assays for the drug discovery & life science markets. This industry-leading portfolio of products and services, under the KINOMEscan®, PathHunter® and BioMAP® brands, are used to aid life science research and enable rapid development of safe and effective biologic and small molecule drugs, by improving research productivity, effectiveness of screening, lead optimization & bioanalytical campaigns, as well as providing predictive tools that deliver physiologically relevant insights on drug molecules from early discovery through pre-clinical development. DiscoverX embodies an innovative approach to creating life science tools that have been widely adopted across the globe in pharmaceutical, biotechnology and academic laboratories. Learn more at discoverx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rapidly-screen-molecules-for-novel-immuno-oncology-therapeutics-with-checkpoint-receptor-screening-and-profiling-services-300412938.html
SOURCE DiscoveRx Corporation